Brian S. Henick

3.8k total citations
57 papers, 854 citations indexed

About

Brian S. Henick is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Brian S. Henick has authored 57 papers receiving a total of 854 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 18 papers in Immunology. Recurrent topics in Brian S. Henick's work include Cancer Immunotherapy and Biomarkers (24 papers), Immunotherapy and Immune Responses (10 papers) and CAR-T cell therapy research (10 papers). Brian S. Henick is often cited by papers focused on Cancer Immunotherapy and Biomarkers (24 papers), Immunotherapy and Immune Responses (10 papers) and CAR-T cell therapy research (10 papers). Brian S. Henick collaborates with scholars based in United States, Greece and Australia. Brian S. Henick's co-authors include Roy S. Herbst, Kurt A. Schalper, David L. Rimm, Yuting Liu, Jon Zugazagoitia, Scott Gettinger, Fahad Shabbir Ahmed, Glenn Heller, William R. Berry and Howard I. Scher and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and ACS Nano.

In The Last Decade

Brian S. Henick

52 papers receiving 839 citations

Peers

Brian S. Henick
Prakash Kharel United States
Satoshi Muto Japan
Yang Qu China
Jacob J. Orme United States
Yavar Shiravand Italy
Brian Belmontes United States
Federica Biello Italy
Anwaar Saeed United States
Ai Maeda Japan
Jiachen Xu China
Prakash Kharel United States
Brian S. Henick
Citations per year, relative to Brian S. Henick Brian S. Henick (= 1×) peers Prakash Kharel

Countries citing papers authored by Brian S. Henick

Since Specialization
Citations

This map shows the geographic impact of Brian S. Henick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian S. Henick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian S. Henick more than expected).

Fields of papers citing papers by Brian S. Henick

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian S. Henick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian S. Henick. The network helps show where Brian S. Henick may publish in the future.

Co-authorship network of co-authors of Brian S. Henick

This figure shows the co-authorship network connecting the top 25 collaborators of Brian S. Henick. A scholar is included among the top collaborators of Brian S. Henick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian S. Henick. Brian S. Henick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
May, Michael, Jonathan Lee, Xin Ma, et al.. (2025). The impact of eligibility criteria on Kirsten rat sarcoma G12C inhibitor trials in patients with non–small cell lung cancer. JNCI Journal of the National Cancer Institute. 118(1). 49–57.
2.
Wilky, Breelyn A., Gary K. Schwartz, Michael S. Gordon, et al.. (2025). Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas. Journal of Clinical Oncology. 43(11). 1358–1368. 9 indexed citations
3.
Henick, Brian S., et al.. (2025). Squamous cell cancers of the aero-upper digestive tract: A unified perspective on biology, genetics, and therapy. Cancer Cell. 43(2). 178–194. 2 indexed citations
4.
5.
Britton, William, et al.. (2024). Advancements in TGF-β Targeting Therapies for Head and Neck Squamous Cell Carcinoma. Cancers. 16(17). 3047–3047. 1 indexed citations
6.
Reckamp, Karen L., Mary W. Redman, Konstantin H. Dragnev, et al.. (2024). SWOG S2302, PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (PR) versus standard of care (SOC) for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer.. Journal of Clinical Oncology. 42(16_suppl). TPS8657–TPS8657. 5 indexed citations
7.
Thomas, Sajeve, Brian S. Henick, Rom S. Leidner, et al.. (2024). Initial data from a phase 1, first-in-human clinical trial for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2542–2542.
8.
Henick, Brian S., Peter D. Koch, Justin F. Gainor, et al.. (2024). Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings. Journal for ImmunoTherapy of Cancer. 12(12). e009301–e009301. 4 indexed citations
9.
Bukhari, Shoiab, Kieran Adam, Shalom Lerrer, et al.. (2024). Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity. Journal for ImmunoTherapy of Cancer. 12(3). e008482–e008482. 4 indexed citations
10.
Bukhari, Shoiab, Shalom Lerrer, Robert Winchester, et al.. (2024). PD-1 signaling uncovers a pathogenic subset of T cells in inflammatory arthritis. Arthritis Research & Therapy. 26(1). 32–32. 6 indexed citations
11.
Henick, Brian S., et al.. (2023). Severe scalp ulcerations and granulomata during treatment with amivantamab. SHILAP Revista de lepidopterología. 13. 100273–100273. 2 indexed citations
12.
13.
Dunbar, Karen J., Tatiana A. Karakasheva, Qiaosi Tang, et al.. (2023). Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma. Molecular Cancer Research. 21(7). 741–752. 13 indexed citations
14.
Washburn, Robert S., Radomir Kratchmarov, Shana M. Coley, et al.. (2022). Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy. Cancer Immunology Research. 11(2). 164–170. 13 indexed citations
15.
Washburn, Robert S., et al.. (2022). Cutting Edge: Promoting T Cell Factor 1+ T Cell Self-Renewal to Improve Programmed Cell Death Protein 1 Blockade. The Journal of Immunology. 209(4). 660–664. 7 indexed citations
16.
Henick, Brian S., Franz Villarroel‐Espíndola, Ila Datar, et al.. (2022). Quantitative tissue analysis and role of myeloid cells in non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. 10(7). e005025–e005025. 7 indexed citations
17.
Datar, Ila, Sacha C. Hauc, Shruti Desai, et al.. (2021). Spatial Analysis and Clinical Significance of HLA Class-I and Class-II Subunit Expression in Non–Small Cell Lung Cancer. Clinical Cancer Research. 27(10). 2837–2847. 26 indexed citations
18.
Liu, Yuting, Jon Zugazagoitia, Fahad Shabbir Ahmed, et al.. (2019). Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy. Clinical Cancer Research. 26(4). 970–977. 225 indexed citations
19.
Ricciuti, Biagio, Abdul Rafeh Naqash, Brian S. Henick, et al.. (2019). OA03.07 Immune-Related Adverse Events and Clinical Outcome to Anti PD-1 Axis Inhibition in SCLC: A Multicenter Retrospective Analysis. Journal of Thoracic Oncology. 14(10). S213–S214. 3 indexed citations
20.
Datar, Ila, Miguel F. Sanmamed, Jungmin Choi, et al.. (2017). In patients with advanced non-small cell lung cancer (NSCLC) LAG-3 is expressed on activated TILs and predicts resistance to PD-1 axis blockers. Annals of Oncology. 28. xi5–xi5. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Prakash Kharel Breakdown of academic impact, for papers by Satoshi Muto Breakdown of academic impact, for papers by Yang Qu Breakdown of academic impact, for papers by Jacob J. Orme Breakdown of academic impact, for papers by Yavar Shiravand Breakdown of academic impact, for papers by Brian Belmontes Breakdown of academic impact, for papers by Federica Biello Breakdown of academic impact, for papers by Anwaar Saeed Breakdown of academic impact, for papers by Ai Maeda Breakdown of academic impact, for papers by Jiachen Xu
Rankless by CCL
2026